ULBP2 and breast carcinoma: miR-302c and miR-520c negatively regulated the expression of MICA/B and ULBP2 upon 1-α,25-dihydroxyvitamin D3 (1,25(OH)2D3) treatment in leukemia (Kasumi-1) and breast cancer (MDA-MB-231) cell lines, by directly targeting the 3′-UTR, and their inhibition resulted in an increased resistance to NK cell killing activity [63].